BridgeMD
Efficacy and safety of minidosing lysergic acid diethylamide (LSD) for chronic cluster headache: a randomized placebo-controlled study
EU CTIS ID: 2024-520305-39-00
What this study is testing
To evaluate the efficacy and safety of LSD 25μg every 3 days for 3 weeks in chronic cluster headache.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 16-75 years of age at screening
- Diagnosis of chronic cluster headache according to ICHD-3 criteria.
- At the screening visit, a retrospective assessment of the 4 weeks prior to screening meets all of the following: An average of at least 8 attacks per week; Attack frequency in each week is within a 40% window around the average.
- At the randomization visit, both of the following are met (inclusion criterion not to be shared with the subject): an average of at least 8 attacks per week; No absence of attacks on more than 2 consecutive days; Attack frequency in each week is within a 40% window around the average
- Subject has signed informed consent; consent by proxy is not allowed.
- Subject is aware of and willing to conform to all study procedures and visits.
You likely can't join if
- Known or suspected structural cause for cluster headache attacks (cluster-mimics).
- Positive drug screen at screening.
- History of cardiac valvular disease or disorder.
- History or evidence of cognitive disorder at screening; MOCA <26 at screening.
- History of significant and active medical comorbidities, including but not limited to hepatic, renal, urethral, vascular or cardiac valvular disease, cardiac rhythm disorders and hypertension (according to professional judgement).
- Women who are pregnant or nursing.
See the full eligibility criteria
Who can join
- 16-75 years of age at screening
- Diagnosis of chronic cluster headache according to ICHD-3 criteria.
- At the screening visit, a retrospective assessment of the 4 weeks prior to screening meets all of the following: An average of at least 8 attacks per week; Attack frequency in each week is within a 40% window around the average.
- At the randomization visit, both of the following are met (inclusion criterion not to be shared with the subject): an average of at least 8 attacks per week; No absence of attacks on more than 2 consecutive days; Attack frequency in each week is within a 40% window around the average
- Subject has signed informed consent; consent by proxy is not allowed.
- Subject is aware of and willing to conform to all study procedures and visits.
- Subjects are on a stable regimen of cluster headache prophylactics (defined in table 1 of study protocol) and agree not to increase the dose nor start a new cluster prophylactic during the screening and double-blind phase of the study.
- Women of child-bearing potential must test negative for pregnancy at screening and start of treatment.
- All females must agree either to abstain from sexual intercourse with a male partner, or to use of a reliable method of birth control during screening and treatment period as well as for 1 week after the last dose of study drug. Acceptable methods of birth control for this study include: oral contraceptives; implantable contraceptives; injectable contraceptives; a contraceptive patch; barrier methods such as diaphragms with contraceptive jelly, cervical caps with contraceptive jelly, condoms with contraceptive foam, or intrauterine devices; or a partner with vasectomy. Birth control is not required if the female is infertile due to surgical sterilization (hysterectomy, or at least 6 weeks after surgical bilateral oophorectomy or tubal ligation) confirmed by medical history or menopause. Menopause is defined as spontaneous amenorrhea for at least 12 months not induced by a medical condition.
What rules you out
- Known or suspected structural cause for cluster headache attacks (cluster-mimics).
- Positive drug screen at screening.
- History of cardiac valvular disease or disorder.
- History or evidence of cognitive disorder at screening; MOCA <26 at screening.
- History of significant and active medical comorbidities, including but not limited to hepatic, renal, urethral, vascular or cardiac valvular disease, cardiac rhythm disorders and hypertension (according to professional judgement).
- Women who are pregnant or nursing.
- Blood pressure at screening >160/100; pulse rate at screening >100 beats per minute.
- eGFR at screening <60 ml/min.
- Other headaches, if the patient cannot reliably distinguish them from attacks of cluster headache.
- Current use of any of the prohibited prophylactic cluster headache treatments (defined in study protocol table 1), unless used under de conditions described in table 1 of the study protocol.
- History of or actual psychotic or bipolar disorder; first degree relative(s) with (a history of) psychotic or bipolar disorder
- A score of 6 or more on the ‘Ervaringenlijst’ (PQ-16).
- History of suicidal intention or attempt and/or first degree relative with known history of suicidal intention or attempt.
- The subject is at significant risk of suicide (at the at the discretion of the investigator or when in the C-SSRS a subject answers ‘yes’ to suicidal ideation questions 4 or 5 or to suicidal behaviour).
- Active abuse of alcohol and/or any current use or severe past abuse of Schedule I listed drugs (Dutch: lijst 1 van de Opiumwet), at the discretion of the investigator (based on type of drug, reason for abuse (medical or non-medical), duration of abuse and abstinence, professional, relational and social impact, amongst others).
- Medicinal or recreational use of cannabis, if any of the following applies: a score of ≥8 on the CUDIT-R is attained OR cannabis use within the 6 weeks prior to screening OR abstinence from using cannabis is refused for the duration of the study
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.